Last data update: May 06, 2024. (Total: 46732 publications since 2009)
Records 1-6 (of 6 Records) |
Query Trace: Jacques-Carroll L[original query] |
---|
Building immunization decision-making capacity within the World Health Organization European Region
Mosina L , Sankar Datta S , Shefer A , Cavallaro KF , Henaff L , Steffen CA , Jacques-Carroll L . Vaccine 2020 38 (33) 5109-5113 A National Immunization Technical Advisory Group (NITAG) is a multi-disciplinary body of national experts that provides evidence-based recommendations to policy-makers, assisting them in making sound immunization policy and programme decisions. The World Health Organization (WHO) Regional Office for Europe is working to strengthen the capacity of newly-established NITAGs and has targeted efforts on low- and middle-income countries. The Regional Office, in collaboration with WHO Headquarters and USA Centers for Disease Control and Prevention (CDC), developed a new training strategy and held training workshops to improve NITAGs' functioning and ability to make evidence-based recommendations. Feedback from countries that participated in trainings indicated that the updated training materials and interactive approach with follow-up technical support enabled them to align their NITAG charters and processes with WHO recommendations. To ensure continued progress, global and regional partners such as WHO and CDC should continue providing technical support to recently established NITAGs. |
Factors associated with human immunodeficiency virus screening of women during pregnancy, labor and delivery, United States, 2005-2006
Fitz Harris LF , Taylor AW , Zhang F , Borkowf CB , Arthur BC , Jacques-Carroll L , Wang SA , Nesheim SR . Matern Child Health J 2014 18 (3) 648-56 The purpose of this study was to estimate prenatal human immunodeficiency virus (HIV) screening rates prior to and on admission to labor and delivery (L&D) and to examine factors associated with HIV screening, including hospital policies, with a comparison of HIV and hepatitis B prenatal screening practices and hospital policies. In March 2006, a survey of hospitals (n = 190) and review of paired maternal and infant medical records (n = 4,762) were conducted in 50 US states, DC, and Puerto Rico. Data from the survey and medical record review were analyzed using SAS software v9.2 (SAS Institute, Cary, NC). HIV testing before delivery occurred among 3,438 women (73.9 %); African American and Hispanic women were more likely to be tested than white women [aOR 2.22, 95 % CI (1.6-3.1) and aOR 1.55, 95 % CI (1.1-2.2), respectively]. Among women without previous HIV testing, 138 (16.6 %) were tested after admission to labor and delivery. Policies to test women with undocumented HIV status in at delivery were present in 65 (36.3 %) hospitals. HIV testing after admission to L&D was more likely in hospitals with policies to test women with undocumented HIV status [aOR 5.91, 95 % CI (2.0-17.8)]. Overall, policies and screening practices for HIV were consistently less prevalent than those for hepatitis B. Many women are not being routinely screened for HIV before or at delivery. Women with unknown HIV status were more likely to be tested in L&D in hospitals with testing policies. |
The National Perinatal Hepatitis B Prevention Program, 1994-2008
Smith EA , Jacques-Carroll L , Walker TY , Sirotkin B , Murphy TV . Pediatrics 2012 129 (4) 609-16 OBJECTIVE: To determine the trends and outcomes of the national Perinatal Hepatitis B Prevention Program (PHBPP) for infants born from 1994 to 2008. METHODS: PHBPPs in state and city public health jurisdictions annually submitted program outcome reports to the Centers for Disease Control and Prevention. The annual number of births to hepatitis B surface antigen (HBsAg)-positive women was estimated and used to evaluate the percentage of PHBPP-identified HBsAg-positive pregnant women. PHBPP reports were used to assess program objectives achieved, and infant outcomes by 12 to 24 months of age. RESULTS: From 1994 to 2008, the estimated number of annual births to HBsAg-positive women increased from 19,208 to 25,600 (P < .001). The annual number of PHBPP-managed infants increased (P < .001), comprising 40.8% to 50.5% of the estimated number. On average, 94.4% of PHBPP-managed infants received hepatitis B immunoglobulin and hepatitis B vaccine within 1 day of birth. The percentage of infants who completed the vaccine series by age 12 months decreased from 86.0% to 77.7% (P = .004), but the percentage who received postvaccination testing increased from 25.1% to 56.0% (P < .001). Incidence of chronic hepatitis B virus infection among tested infants decreased from 2.1% in 1999 to 0.8% in 2008 (P = .001). CONCLUSIONS: The PHBPP achieved substantial progress in preventing perinatal hepatitis B virus infection in the United States, despite an increasing number of at-risk infants. Significant gaps remain in identifying HBsAg-positive pregnant women, and completing management and assessment of their infants to ensure prevention of perinatal hepatitis B virus transmission. |
Progress in newborn hepatitis B vaccination by birth year cohorts-1998-2007, USA
Zhao Z , Murphy TV , Jacques-Carroll L . Vaccine 2011 30 (1) 14-20 BACKGROUND: In 1999, the American Academy of Pediatrics (AAP) and the U.S. Public Health Service (USPHS), issued a joint statement on thimerosal in vaccines, which advised clinicians to temporarily postpone the first dose of hepatitis B vaccine for infants born to hepatitis B surface antigen (HBsAg)-negative women. In 2005, the Advisory Committee on Immunization Practices (ACIP) updated the strategy to improve prevention of perinatal and early childhood hepatitis B virus (HBV) transmission. OBJECTIVES: To evaluate the progress in hepatitis B birth dose vaccination coverage in birth year cohort from 1998 to 2007 and assess the impact of changes in ACIP recommendations on the birth dose coverage. METHODS: Birth year cohort study of hepatitis B birth dose vaccination status of 200,865 children aged 19-35 months in the United States and by selected socio-demographic factors; percentage increases of hepatitis B birth dose vaccination coverage between two consecutive birth year cohorts from 1998 to 2007. RESULTS: From 1998 to 1999, hepatitis B birth dose vaccination coverage declined overall in the United States and among selected socio-demographic groups (P<0.001). Conversely, from 1999 to 2007 hepatitis B birth dose vaccination coverage increased significantly by birth year cohort (P<0.001), from approximately 30% in the 1999 birth year cohort to approximately 60% in the 2007 birth year cohort. The first significant increase in hepatitis B birth dose vaccination coverage occurred from 2000 to 2001 birth year cohort. Coverage increases ranged from 8.4% to 11.9% (P<0.001) in the U.S. and across all socio-demographic strata. The second largest increase in hepatitis B birth dose vaccination coverage occurred from 2005 to 2006 birth year cohort in the U.S. and among almost all socio-demographic strata, ranging from 5.6% to 8.7% (P<0.001). Forty-one of the 50 states and the District of Columbia (80%) in the U.S. had increases in hepatitis B birth dose vaccination coverage from 2005 to 2006 birth year cohort. CONCLUSIONS: The United States has made substantial progress in increasing hepatitis B birth dose vaccination and recovered from coverage declines associated with temporary postponement of the birth dose in 1999. The hepatitis B birth dose coverage in the U.S. remains substantially below the Healthy People 2020 target of 85%. |
Estimating the number of births to hepatitis B virus-infected women in 22 States, 2006
Din ES , Wasley A , Jacques-Carroll L , Sirotkin B , Wang S . Pediatr Infect Dis J 2011 30 (7) 575-9 BACKGROUND: Estimating the annual number of births to hepatitis B virus (HBV)-infected women is essential for monitoring efforts to prevent perinatal HBV transmission. We describe a method for estimating births to HBV-infected women in 22 states during 2006. METHODS: The number of births to HBV-infected women was calculated by (1) multiplying the number of US/Canadian-born mothers stratified by US race/ethnicity-specific HBV prevalence estimates, and (2) adding the number of foreign-born mothers stratified by their region of birth and multiplied by region-specific HBV prevalence estimates. RESULTS: Of 2,359,912 births, an estimated 16,608 (0.7%) were to HBV-infected women. Foreign-born women, who represented 25.3% of all mothers, accounted for 80.6% of estimated HBV-infected mothers. Estimated foreign-born HBV-infected mothers were from Southeast Asia (31.2%), East Asia (21.2%), and Africa (13.8%). Non-Hispanic blacks represented 55.1% of US/Canadian-born HBV-infected mothers. Compared with a previous estimate, which considers foreign-born status only for Asian/Pacific Islander mothers, this method estimated an additional 3000 births to HBV-infected women. CONCLUSIONS: Incorporating maternal country of birth and region-specific HBV infection prevalence likely enhances estimation of births to HBV-infected women in the United States. According to our estimate, approximately 10,000 births to HBV-infected women were not identified by state and local health departments in 22 states. |
An investigation of perinatal Hepatitis B virus infections among a high risk population: the delivery hospital as a safety net
Fischer G , Wang S , Ahring S , Fowler K , Hainline S , Chinglong M , Jacques-Carroll L , Bell B , Williams I . Pediatr Infect Dis J 2009 28 (7) 593-7 BACKGROUND: There was an increase in perinatal hepatitis B virus (HBV) infections in one Arkansas county that disproportionately affected Marshallese infants. METHODS: An estimated 6000 to 10,000 Marshallese, from the Pacific island nation of the Marshall Islands where HBV is highly endemic, live in one Arkansas county. We conducted a retrospective review of hospital and health department records from 2003 to 2005 in that county. We compared maternal screening for hepatitis B surface antigen (HBsAg) between Marshallese and non-Marshallese. We also reviewed birth and immunization records for infants born to HBsAg-positive mothers to evaluate postexposure prophylaxis (PEP). RESULTS: Ten percent (n = 41) of Marshallese births and 0.1% (n = 15) of non-Marshallese births were to HBsAg-positive women. Among those born to HBsAg-positive women, Marshallese and non-Marshallese infants were equally likely to receive PEP with hepatitis B vaccine (98% vs. 100%; P[r] = 0.98) and hepatitis B immune globulin (HBIG) ≤12 hours after birth (88% vs. 87%; P = 0.91). Approximately 57% (n = 32) of all infants born to HBsAg-positive women were tested for perinatal HBV infection. The proportion of Marshallese (17%) and non-Marshallese (13%) infants who tested positive for HBsAg at ages 9 to 25 months was similar (P = 0.78). Receiving HBIG >12 hours after birth was the only factor significantly associated with infection. CONCLUSIONS: Although HBV infection was more prevalent among Marshallese compared with non-Marshallese women, there were no differences in infant receipt of PEP and perinatal HBV infection. Delivery hospitals in this county had standing orders to administer hepatitis B vaccine to all newborns, which likely provided a safety net to prevent perinatal HBV transmission in this high-risk population. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure